The new era of biotech insulin analogues

Summary Many of the structural properties of insulin have evolved in response to the requirements of biosynthesis, processing, transport and storage in the pancreatic beta cells, properties that are not necessary for the biological action of the hormone. It is therefore not surprising that wild-type insulin has far from optimal characteristics for replacement therapy. For example, native human insulin self-associates to hexameric units, which limits the possibilities for the absorption of the molecule by various routes. During the last decade new techniques of molecular design have emerged and recombinant DNA technology offers new and exciting opportunities for rational protein drug design. This review describes examples of recent advances in insulin engineering aimed at optimizing the hormone for therapy. Such approaches focus on improvements in the pharmacokinetic properties, storage stability, and feasibility for less intrusive routes of administration [Diabetologia (1997) 40: S 48–S 53].

[1]  A. Banga,et al.  Characterization of in Vitro Transdermal Iontophoretic Delivery of Insulin , 1993 .

[2]  Z Trajanoski,et al.  Pharmacokinetic Model for the Absorption of Subcutaneously Injected Soluble Insulin and Monomeric Insulin - Analogues - Pharmakokinetisches Modell für die Absorption von subkutan injiziertem löslichem Insulin und monomeren Insulinanaloga , 1993, Biomedizinische Technik. Biomedical engineering.

[3]  S. Jacobsen,et al.  Potential novel methods for insulin administration: I. Iontophoresis. , 1984, Biomedica biochimica acta.

[4]  D. Robbins,et al.  Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients , 1987, Diabetes.

[5]  B H Frank,et al.  Altering the association properties of insulin by amino acid replacement. , 1992, Protein engineering.

[6]  J. Trimmer,et al.  Transdermal delivery of human insulin to albino rabbits using electrical current. , 1989, The American journal of the medical sciences.

[7]  J. Brange,et al.  Monomeric insulins obtained by protein engineering and their medical implications , 1988, Nature.

[8]  L. John,et al.  Blood glucose control in diabetic rats by transdermal iontophoretic delivery of insulin , 1988 .

[9]  D R Owens,et al.  Monomeric Insulins and Their Experimental and Clinical Implications , 1990, Diabetes Care.

[10]  J. Riviere,et al.  Model systems in iontophoresis--transport efficacy. , 1992, Acta pharmaceutica Nordica.

[11]  J. Brange,et al.  Insulin structure and stability. , 1993, Pharmaceutical biotechnology.

[12]  D R Owens,et al.  Subcutaneous Insulin Absorption Explained by Insulin's Physicochemical Properties: Evidence From Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans , 1991, Diabetes Care.

[13]  D. Owens,et al.  Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetes , 1990, The Lancet.

[14]  J. Brange.  Stability of insulin : studies on the physical and chemical stability of insulin in pharmaceutical formulation , 1994 .

[15]  L. Heinemann,et al.  Action Profile of the Rapid Acting Insulin Analogue: Human Insulin B28Asp , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[16]  C. Cullander.  What are the pathways of iontophoretic current flow through mammalian skin , 1992 .

[17]  W. Shi,et al.  Transdermal Iontophoretic Delivery of Therapeutic Peptides/Proteins I: Insulin , 1987, Annals of the New York Academy of Sciences.

[18]  D. Owens,et al.  Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects. , 1988, BMJ.

[19]  C. Binder.  Absorption of injected insulin. A clinical-pharmacological study. , 2009, Acta pharmacologica et toxicologica.

[20]  B. Kári.  Control of Blood Glucose Levels in Alloxan-diabetic Rabbits by Iontophoresis of Insulin , 1986, Diabetes.

[21]  D. Owens,et al.  Comparison of Subcutaneous Soluble Human Insulin and Insulin Analogues (AspB9, GluB27; AspB10; AspB28) on Meal-Related Plasma Glucose Excursions in Type I Diabetic Subjects , 1991, Diabetes Care.

[22]  Y. Chien,et al.  Facilitated transdermal transport of insulin. , 1987, Journal of pharmaceutical sciences.

[23]  D R Owens,et al.  Absorption Kinetics and Action Profiles of Subcutaneously Administered Insulin Analogues (AspB9GluB27, AspB10, AspB28) in Healthy Subjects , 1991, Diabetes Care.

[24]  R. Ratner,et al.  Persistent Cutaneous Insulin Allergy Resulting From High-Molecular-Weight Insulin Aggregates , 1990, Diabetes.

[25]  D. Robbins,et al.  Free Covalent Aggregates of Therapeutic Insulin in Blood of Insulin-Dependent Diabetics , 1987, Diabetes.

[26]  J. Brange,et al.  Chemical stability of insulin. 5. Isolation, characterization and identification of insulin transformation products. , 1992, Acta pharmaceutica Nordica.

[27]  D. Howey,et al.  [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin , 1994, Diabetes.